% ============================================================================
% CONSTRAINT STORY: lsd_microdosing_professional_openness
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2026-02-26
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_lsd_microdosing_professional_openness, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    constraint_indexing:constraint_classification/3,
    constraint_indexing:directionality_override/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: lsd_microdosing_professional_openness
 *   human_readable: The Permanent Openness Shift from Microdosing
 *   domain: psychological/professional/biochemical
 *
 * SUMMARY:
 *   The emergence of LSD microdosing in technology and creative sectors
 *   represents a constraint that blurs biological fact with labor market
 *   extraction. Individuals adopt sustained low-dose LSD (typically 10-20
 *   micrograms, 2-4 times weekly) to increase the personality dimension of
 *   openness to experience, driven by competitive pressure in
 *   innovation-intensive industries. The neurochemical effect is measurable
 *   and durable during active dosing; the constraint lies in the structural
 *   inability to exit without career penalty. The permanent or near-permanent
 *   nature of the openness shift (if verified) creates a biochemical lock-in
 *   that functions as a snare: workers cannot undo the decision to microdose
 *   without cognitive regression. The pharmaceutical benefit (enhanced
 *   creative flexibility, reduced institutional resistance to change) flows
 *   primarily to employers and the cognitive enhancement economy; the cost
 *   (pharmaceutical dependency, legal risk, neurological uncertainty, reduced
 *   autonomy over personality) is borne by the microdosing professional. The
 *   constraint exhibits theater because regulatory prohibition persists while
 *   black-market adoption becomes normalized in professional culture. The
 *   analysis must distinguish between the neuroscientific fact (openness can
 *   be chemically enhanced) and the social structure (competitive pressure
 *   transforms enhancement from option to necessity).
 *
 * KEY AGENTS:
 *   - Microdosing Professional: Primary victim (powerless/trapped) — adopter seeking competitive advantage; locked into dosing schedule by neurochemical dependency and career risk
 *   - Non-Adopting Peer: Secondary victim (moderate/constrained) — displaced by new cognitive standard; faces hiring/promotion penalties without pharmaceutical intervention
 *   - Technology Company / Creative Firm: Primary beneficiary (institutional/arbitrage) — captures productivity gains from elevated-openness workforce; can adjust hiring profiles or exit strategy
 *   - Pharmaceutical Supply Chain: Structural beneficiary (institutional/arbitrage) — LSD manufacturers and distribution networks profit from normalized professional use
 *   - Professional Standards Body / Medical Association: Institutional actor (organized/constrained) — faces conflict between ethics enforcement and market normalization; benefits from silence, constrained by liability
 *   - Drug Control Regulatory Authority: Institutional actor (institutional/arbitrage) — maintains legal prohibition while unable to prevent shadow-market adoption; benefits from regulatory theater
 *   - Analytical Observer: Civilizational view (analytical/analytical) — risks naturalizing biochemical fact as inevitable, obscuring structural choice about labor market design
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(lsd_microdosing_professional_openness, 0.52).
domain_priors:suppression_score(lsd_microdosing_professional_openness, 0.68).
domain_priors:theater_ratio(lsd_microdosing_professional_openness, 0.58).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(lsd_microdosing_professional_openness, extractiveness, 0.52).
narrative_ontology:constraint_metric(lsd_microdosing_professional_openness, suppression_requirement, 0.68).
narrative_ontology:constraint_metric(lsd_microdosing_professional_openness, theater_ratio, 0.58).

% --- Constraint claim ---
narrative_ontology:constraint_claim(lsd_microdosing_professional_openness, snare).
narrative_ontology:human_readable(lsd_microdosing_professional_openness, "The Permanent Openness Shift from Microdosing").
narrative_ontology:topic_domain(lsd_microdosing_professional_openness, "psychological/professional/biochemical").

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(lsd_microdosing_professional_openness, technology_companies).
narrative_ontology:constraint_beneficiary(lsd_microdosing_professional_openness, creative_industries).
narrative_ontology:constraint_beneficiary(lsd_microdosing_professional_openness, cognitive_enhancement_economy).
narrative_ontology:constraint_victim(lsd_microdosing_professional_openness, microdosing_professionals).
narrative_ontology:constraint_victim(lsd_microdosing_professional_openness, labor_market_autonomy).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: MICRODOSING PROFESSIONAL (SNARE) — Worker who began microdosing to enhance creative performance or cognitive flexibility. The neurochemical change to openness is largely irreversible on the timescale of a career. Cannot exit the constraint: sustained dosing required to maintain competitive advantage; cessation risks cognitive regression and loss of market position. Trapped in pharmaceutical dependency disguised as self-optimization. Maximum experienced extraction.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, snare,
    context(agent_power(powerless),
            time_horizon(biographical),
            exit_options(trapped),
            spatial_scope(global))).

% PERSPECTIVE 2: NON-ADOPTING PEER COHORT (SNARE) — Professionals who refuse or cannot access microdosing. Face systematic disadvantage in hiring, promotion, and creative project allocation. The standard for 'openness' and 'innovativeness' in the labor market is now biochemically elevated. Constrained by career risk and social pressure; cannot opt out without accepting reduced opportunity. Experiencing extraction through competitive displacement.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, snare,
    context(agent_power(moderate),
            time_horizon(biographical),
            exit_options(constrained),
            spatial_scope(national))).

% PERSPECTIVE 3: TECHNOLOGY COMPANY / CREATIVE FIRM (ROPE) — Employer benefits from workforce with elevated openness: faster adaptation to market shifts, higher creative output, reduced institutional resistance to change. Experiences the constraint as coordination: microdosing solves the collective action problem of maintaining cognitive flexibility at competitive scale. Net beneficiary with full exit optionality — can adjust hiring profiles, exit the dependency if market conditions change. Low experienced extraction.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, rope,
    context(agent_power(institutional),
            time_horizon(immediate),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 4: PROFESSIONAL STANDARDS BODY / MEDICAL ESTABLISHMENT (TANGLED ROPE) — Medical associations and credentialing bodies face pressure to either prohibit pharmaceutical cognitive enhancement (coordination function: maintaining professional ethics) or tacitly permit it (extraction: capturing premium fees from microdosers, enabling pharmaceutical company influence). Constrained by inability to enforce prohibition; benefits from fee generation and reduced liability if they remain silent. Active enforcement necessary to prevent normalization, but enforcement capacity is eroding.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, tangled_rope,
    context(agent_power(organized),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 5: REGULATORY FRAMEWORK / DRUG CONTROL SCHEDULING (PITON) — LSD remains Schedule I, creating a legal fiction that the substance has no medical use while professionals use it systematically. The constraint is maintained through institutional inertia: reclassifying LSD would require admitting prior policy error, triggering regulatory cascades. Regulatory theater persists (prohibition) while the actual function (preventing cognitive enhancement) has degraded. Theater ratio is high because the regulatory apparatus continues performatively while market adoption proceeds in shadow economy.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, piton,
    context(agent_power(institutional),
            time_horizon(civilizational),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 6: ANALYTICAL OBSERVER / NEUROPHARMACOLOGY VIEW (MOUNTAIN) — From a biochemical perspective, the permanent shift in personality (increased openness) via sustained LSD exposure appears immutable: the neuroplastic changes to serotonin receptor sensitivity and default mode network connectivity are durable. Openness gain is not a choice but a pharmacological fact. However, this perspective risks naturalizing what is actually a structural choice about labor market incentives and pharmaceutical market design.
constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, mountain,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(universal))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(lsd_microdosing_professional_openness_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, TypePowerless, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(lsd_microdosing_professional_openness, TypeOther, context(agent_power(institutional), _, _, _)),
    TypePowerless \= TypeOther.

test(extraction_signature) :-
    domain_priors:base_extractiveness(lsd_microdosing_professional_openness, E),
    E >= 0.46. % Ensures high-extraction Snare/Tangled territory.

test(piton_threshold) :-
    domain_priors:theater_ratio(lsd_microdosing_professional_openness, TR),
    TR >= 0.70.

:- end_tests(lsd_microdosing_professional_openness_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (0.52): Moderate-high. The microdosing professional gains cognitive advantage but becomes dependent on sustained pharmaceutical input to maintain competitive position. The extraction is not violent or immediately coercive, but it is structural: workers cannot exit without career penalty. The extractiveness has increased over the measurement interval (0.28 → 0.52) as adoption in peer cohorts has made non-adoption a liability rather than a choice. Suppression (0.68): High. Multiple barriers prevent exit: (1) neurochemical dependency—cessation risks cognitive regression; (2) legal risk—LSD possession remains federal crime despite therapeutic use; (3) information asymmetry—long-term safety and reversibility unknown; (4) competitive dynamic—non-adopters face systematic disadvantage; (5) institutional silence—medical profession avoids advising on optimal dosing or cessation. Theater ratio (0.58): Moderate-high and increasing. Regulatory prohibition (schedule I) creates legal fiction that LSD has no medical use while professional use is becoming normalized. Professional societies issue no guidance, creating theater of neutrality masking tacit endorsement. Neurological risk communication is minimal—most microdosers learn protocol from online communities rather than medical professionals. The theater increased over the interval as the gap between legal status and practical adoption widened.
 *
 * PERSPECTIVAL GAP:
 *   The constraint exhibits stark perspectival divergence. The employer (rope perspective) sees a coordination mechanism—solving the collective action problem of workforce adaptability. The microdosing professional (snare perspective) sees an inescapable dependency—the permanent personality shift transforms what began as enhancement into entrapment. The non-adopter (snare perspective) sees a discriminatory labor standard imposed without consent. The pharmaceutical supply chain (rope perspective) sees market alignment—demand and supply finding equilibrium. The regulatory authority (piton perspective) sees institutional theater—prohibition persists while enforcement capacity has degraded. The analytical observer (mountain perspective) risks seeing a law of nature—the biochemical impossibility of reverting personality changes once neuroplasticity has remodeled openness. The perspectival gap reveals that 'openness enhancement' is not a neutral fact but a structural transformation that benefits some actors while extracting from others.
 *
 * DIRECTIONALITY LOGIC:
 *   Directionality is derived from beneficiary/victim status and exit options. The microdosing professional is a victim (bears pharmaceutical cost and legal risk) with trapped exit options (cannot cease without career penalty) → d ≈ 0.95 → high f(d) → high experienced extractiveness. The non-adopting peer is a victim (displaced in labor market) with constrained exit (can leave profession but at career cost) → d ≈ 0.75 → moderate f(d). The employer is a beneficiary (captures productivity gain) with arbitrage exit (can adjust hiring or shift strategy) → d ≈ 0.05 → negative f(d) → negative or minimal experienced extraction. The regulatory authority is a structural beneficiary (maintains discretionary enforcement power) with arbitrage exit (can selectively enforce or reclassify) but constrained by inability to stop market adoption → d overridden to 0.35 to reflect partial beneficiary status. The professional standards body faces conflicted directionality: enforcement would harm members (victims of market penalty), silence enables extraction—modeled as d ≈ 0.55 (symmetric between beneficiary and victim logic).
 *
 * MANDATROPHY ANALYSIS:
 *   RESOLUTION REQUIRED: The constraint resolves mandatrophy by identifying genuine coordination benefit (employers solve workforce adaptability problem) combined with genuine extraction (workers cannot exit). The coordination function is real—openness enables faster institutional adaptation, valuable for innovation-intensive firms. The extraction is also real—workers bear pharmaceutical, legal, and cognitive autonomy costs that are not transparent at the point of adoption. The mandatrophy is NOT 'is this extraction or coordination?' but 'what institutional structure determines who captures the coordination benefit and who bears the extraction cost?' If pharmaceutical dependency is permanent or near-permanent (high confidence in omega_durability_of_openness_gain), workers become trapped—snare classification is correct, mandatrophy is resolved. If dependency is reversible and workers can credibly exit, the constraint becomes a temporary scaffold with sunset logic (open-science bioethics oversight could establish exit protocols). If designer pharmaceutical alternatives emerge, the constraint shifts from snare to tangled rope (regulated pharmaceutical market with both coordination and extraction). Current evidence suggests permanent neuroplasticity dominates, supporting snare classification and high extractiveness.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    durability_of_openness_gain,
    'Is the increase in openness from microdosing permanently neuroplastic, or does it degrade over months/years post-cessation?',
    'Longitudinal neuroimaging and personality assessment of microdosers across 2+ year follow-up; measurement of openness trajectory after dosing cessation in controlled cohorts',
    'If permanent: constraint is immutable (mountain logic). If degrading: constraint becomes extractive dependency (snare logic) — workers must continue dosing or lose market position. Classification hinges on neuropharmacological fact.',
    confidence_without_resolution(low)
).

narrative_ontology:omega_variable(durability_of_openness_gain, empirical, 'Whether openness gains persist after cessation of microdosing').

omega_variable(
    cognitive_ceiling_effect,
    'Does chronic microdosing produce diminishing returns in openness, or does tolerance to LSD maintain stable elevated openness indefinitely?',
    'Dose-response curves in chronic users; measurement of openness gain relative to dose escalation; comparison of cross-sectional openness in high-dose vs low-dose chronic users',
    'If ceiling effect: workers face escalating dosing requirements (snare). If stable: constraint is stable coordination (rope). If increasing returns: workforce cognition becomes bio-dependent without bound (catastrophic snare).',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(cognitive_ceiling_effect, empirical, 'Whether sustained microdosing produces tolerance or stable openness enhancement').

omega_variable(
    labor_market_adoption_threshold,
    'At what percentage workforce adoption does microdosing become a de facto professional requirement rather than an option?',
    'Survey of hiring practices and performance evaluation criteria as adoption spreads; measurement of career penalty for non-adopters across adoption tiers; analysis of job market segmentation by microdosing status',
    'Below 20%: remains optional (moderate snare). 20-50%: becomes quasi-mandatory (strong snare). Above 50%: becomes structural labor market condition (systemic snare). Classification depends on adoption threshold and its visibility to workers.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(labor_market_adoption_threshold, empirical, 'At what adoption rate does microdosing become effectively mandatory').

omega_variable(
    pharmaceutical_dependency_reversibility,
    'Can a professional who microdoses for 5+ years and achieves career advancement via elevated openness credibly return to baseline personality without career disruption?',
    'Qualitative interviews with long-term microdosers attempting cessation; measurement of career outcomes post-cessation; tracking of employer perception changes as openness declines',
    'If fully reversible: constraint is temporary (scaffold). If partially reversible: constraint is moderate snare (extraction window = career span). If irreversible: constraint is permanent snare with long-term exit cost.',
    confidence_without_resolution(low)
).

narrative_ontology:omega_variable(pharmaceutical_dependency_reversibility, empirical, 'Whether professionals can credibly exit microdosing without career loss').

omega_variable(
    emergence_of_designer_alternatives,
    'Will pharmaceutical companies develop designer compounds that increase openness without LSD''s schedule-I status, legal risk, or neurological side effects?',
    'Patent landscape analysis; clinical trial pipeline tracking; regulatory feedback on novel compounds; comparison of development timelines vs LSD acceptance trajectory',
    'If designer compounds emerge: constraint shifts to pharmaceutical company control (tangled rope). If LSD remains cheapest option: constraint remains a snare with black market dependency. If legal rescheduling occurs first: constraint becomes regulated (rope/scaffold). Outcome determines whether beneficiary shifts.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(emergence_of_designer_alternatives, empirical, 'Whether legal pharmaceutical alternatives emerge before widespread LSD adoption').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(lsd_microdosing_professional_openness, 0, 10).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(lsd_micro_tr_t0, lsd_microdosing_professional_openness, theater_ratio, 0, 0.35).
narrative_ontology:measurement(lsd_micro_tr_t5, lsd_microdosing_professional_openness, theater_ratio, 5, 0.48).
narrative_ontology:measurement(lsd_micro_tr_t10, lsd_microdosing_professional_openness, theater_ratio, 10, 0.58).

% Extraction over time
narrative_ontology:measurement(lsd_micro_be_t0, lsd_microdosing_professional_openness, base_extractiveness, 0, 0.28).
narrative_ontology:measurement(lsd_micro_be_t5, lsd_microdosing_professional_openness, base_extractiveness, 5, 0.4).
narrative_ontology:measurement(lsd_micro_be_t10, lsd_microdosing_professional_openness, base_extractiveness, 10, 0.52).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(lsd_microdosing_professional_openness, resource_allocation).
narrative_ontology:affects_constraint(lsd_microdosing_professional_openness, cognitive_enhancement_labor_market_segregation).
narrative_ontology:affects_constraint(lsd_microdosing_professional_openness, pharmaceutical_dependency_economy).
narrative_ontology:affects_constraint(lsd_microdosing_professional_openness, schedule_i_regulatory_capture).

% DUAL FORMULATION NOTE:
% This constraint is downstream of the broader cognitive enhancement economy (higher-level constraint on labor market segmentation by cognitive modification) but represents a distinct structural phenomenon: the use of a specific substance with known neurochemical durability to lock workers into pharmaceutical dependency. The constraint family includes pharmaceutical alternatives (if designer compounds emerge) and regulatory reclassification pathways (if LSD is rescheduled for therapeutic use). Each family member has its own epsilon value reflecting its empirical status and structural control by different actors.

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

constraint_indexing:directionality_override(lsd_microdosing_professional_openness, institutional, 0.35).

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
